PalellaFJJr, DelaneyKM, MoormanACDeclining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.N Engl J Med1998; 338: 85360
2.
MulliganK, GrunfeldC, TaiVWHyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection.J Acquir Immune Defic Syndr2000; 23: 3543
CheneGE, AngeliniE, CotteLRole of long-term nucleoside analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.Clin Infect Dis2002; 34: 64959
5.
KleinD, HurleyL. Do protease inhibitors increase the risk of heart disease in patients with HIV infection?J Acquir Immune Defic Syndrome2002; 30: 4717
6.
Prevention of coronary heart disease in clinical practice.Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.Eur Heart J1998; 19: 1434503
7.
Friis-MollerN, SabinCA, WeberRCombination antiretroviral therapy and the risk of myocardial infarction.N Engl J Med2003; 349: 19932003
8.
CarrA, SamarasK, BurtonSA syndrome of peripheral lipodystrophy hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.AIDS1998; 12: F518
9.
MooserV, CarrA. Antiretroviral therapy-associated hyperlipidaemia in HIV disease.Curr Opin Lipidol2001; 12: 31319
10.
CattelanAM, TrevenzoliM, SassetLIndinavir and systemic hypertension.AIDS2001; 15: 8057
CorcoranCP, GrinspoonS. Diagnosis and treatment of endocrine disorders in the HIV-infected patient.J Int Assoc Physicians AIDS Care1998; 4: 1014
13.
HaffnerSM, LaaksoM, MiettinenHLow levels of sex hormone-binding globulin and testosterone are associated with smaller, denser low density lipoprotein in normoglycemic men.J Clin Endocrinol Metab1996; 81: 3697701
14.
HartgensP, KuipersH. Effects of androgenic-anabolic steroids in athletes.Sports Med2004; 34: 51354
15.
GrunfieldC, KotierDP, HamadehRHypertriglyceridemia in the acquired immunodeficiency syndrome.Am J Med1989; 86: 2731
16.
GrunfeldC, PangM, DoerrlerWLipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.J Clin Endocrinol Metab1992; 74: 104552
17.
FeingoldKR, KraussRM, PangMThe hypertriglyceridemia of acquired immunodeficiency syndrome is associated with an increased prevalence of low density lipoprotein subclass pattern B.J Clin Endocrinol Metab1993; 76: 14237
18.
CarrA, SamarasK, ThorisdottirADiagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet1999; 353: 20939
19.
CahnPE, GatellJM, SquiresKAtazanavir - a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized trials.J Int Assoc Physicians AIDS Care2004; 3: 928
BrinkmanK, ter HofstedeHJ, BurgerDMAdverse effects of reverse transcriptase inhibitors mitochondrial toxicity as common pathway.AIDS1998; 12: 173514
22.
CarrA, MillerJ, LawM, CooperDA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.AIDS2000; 14: F2532
23.
CarrA, SamarasK, ChisholmDJ, CooperDA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia and insulin resistance.Lancet1998; 351: 18813
RiddleTM, KuhelDG, WoollettLAHIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus.J Biol Chem2001; 276: 3751419
26.
NolanD, MallalS. Getting to the HAART of insulin resistance.AIDS2001; 15: 203741
27.
MurataH, HruzPW, Mueckler. The mechanism of insulin resistance caused by HIV protease inhibitor therapy.J Biol Chem2000; 275: 202514
28.
BetteridgeDJ, MorrellJM. Clinicians’ Guide to Lipids and Coronary Heart Disease, 2nd edn.London: Hodder Arnold, 2003
29.
FriedewaldWT, LevyRI, FredricksonDS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem1972; 18: 499502
30.
LiangJS, DistlerO, CooperDAHIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for PI-induced hyperlipidemia.Nat Med2001; 7: 132731
31.
KwiterovichPOJr. The antiatherogenic role of high-density lipoprotein cholesterol.Am J Cardiol1998; 82: 13Q21Q
32.
FauvelJ, BonnetE, RuidavetsJBAn interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients.AIDS2001; 15: 2397406
33.
ListerRK, YouleM, NairDRLatent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors.Lancet1999; 353: 1678
34.
StamlerJ, WentworthD, NeatonJD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous or graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).JAMA1986; 256: 28238
35.
KannelWB. High-density lipoproteins: epidemiologic profile and risks of coronary artery disease.Am J Cardiol1983; 52: 9B12B
36.
BaintonD, MillerNE, BoltonCHPlasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men. The Caerphilly and Speedwell Collaborative Heart Disease Studies.Br Heart J1992; 68: 606
37.
DownsJR, ClearfieldM, WeisSPrimary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex-CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.JAMA1998; 279: 161522
38.
ShepherdJ, CobbeSM, FordIPrevention of coronary heart disease with pravastatin in men with hypercholestrolemia.N Eng J Med1995; 333: 13017
39.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).Lancet1994; 344: 13839
40.
SacksFM, PfefferMA, MoyeLARationale and design of a secondary prevention trial of lowering normal plasma cholesterol levels after acute myocardial infarction: the Cholesterol and Recurrent Events trial (CARE).Am J Cardiol1991; 68: 143616
41.
LIPID Study Group.Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.N Engl J Med1998; 339: 134957
42.
Heart Protection Study Collaborative Group.MRC /BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial.Lancet2002; 360: 722
43.
NCEP Expert Panel.Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Final report.Circulation2002; 106: 3143121
44.
De BackerG, AmbrosioniE, Borch-JohnsenKEuropean guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.Eur Heart J2003; 24: 160110
45.
MalmbergK, YusufS, GersteinHCImpact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry.Circulation2000; 102: 101419
46.
HaffnerSM, AlexanderCM, CookTJReduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study.Arch Intern Med1999; 159: 26617
47.
PyoralaK, PedersenTR, KjekshusJCholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).Diabetes Care1997; 20: 61420
48.
GoldbergRB, MelliesMJ, SacksFMCardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial.The CARE Investigators Circulation1998; 98: 251319
49.
CollinsR, ArmitageJ, ParishSMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group.Lancet2003; 361: 200516
50.
BrindleP, EmbersonJ, LampeFPredictive accuracy of the Framingham coronary risk score in British men: prospective cohort study.BMJ2000; 327: 126770
51.
WilliamsB, PoulterNR, BrownMJBritish Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary.BMJ2004; 328: 63410
52.
KnoppRH. Drug treatment of lipid disorders.N Engl J Med1999; 341: 498511
53.
FichtenbaumCJ, GerberJG, RosenkranzSLPharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047.AIDS2002; 16: 56977
54.
BenesicA, ZillyM, KlugeFLipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.Infection2004; 32: 22933
55.
CalzaL, ManfrediR, ChiodoF. Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.Infection2002; 30: 2631
56.
BallantyneCM, HouriJ, NotarbartoloAEffect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomised, double-blind trial.Circulation2003; 107: 240915
57.
ShepherdJ. The role of the exogenous pathway in hyper-cholesterolaemia.Eur Heart J Suppl2001; 3 (Suppl E): E25
58.
GuytonJR, CapuzziDM. Treatment of hyperlipidemia with combined niacin-statin regimens.Am J Cardiol1998; 82: 82U4U
59.
BaysHE, SteinEA. Pharmacotherapy for dyslipidaemia -current therapies and future agents.Expert Opin Pharmacother2003; 4: 190138
60.
Kris-EthertonPM, HarrisWS, AppelLJ. American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease.Circulation2002; 106: 274757
61.
CarrA, SamarasK, ThorisdottirADiagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study.Lancet1999; 353: 20939
62.
ListerRK, YouleM, NairDRLatent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors.Lancet1999; 353: 1678
